Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 104
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cancer Res ; 47(9): 2407-12, 1987 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-2436764

RESUMO

A review of the literature on the effect of hypoxia on in vitro drug sensitivity had suggested that there was consistently more cytotoxicity under hypoxic conditions for the drugs misonidazole and mitomycin C while there was much conflicting data for the drugs Adriamycin and bleomycin. We have examined the effect of oxygen on the cellular response of Ehrlich's ascites tumor cells to the drugs mitomycin C, misonidazole, Adriamycin, and bleomycin. Significant differences were observed when we compared the cytotoxicity of mitomycin C and misonidazole as a function of oxygen concentration. For the drugs Adriamycin and bleomycin no differential effects of oxygen were noted for a 1-h drug exposure with hypoxia while some differences were noted only for bleomycin for an 8-h drug exposure time. Because differences dependent on oxygen concentration were observed for some drugs but not others at the same experimental conditions, and as indicated by a review of the literature, it is suggested that some of the conflicting data in the literature with respect to some of these drugs may be cell-line dependent. Other variables which may also be of importance were the duration of drug exposure time in hypoxia and cell density. The observed oxygen concentration-dependent changes in cell survival for the Ehrlich cells with drugs examined could not be explained on the basis of changes in drug-induced cellular oxygen consumption.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Ehrlich/tratamento farmacológico , Oxigênio/farmacologia , Animais , Bleomicina/uso terapêutico , Sobrevivência Celular/efeitos dos fármacos , Doxorrubicina/uso terapêutico , Matemática , Misonidazol/uso terapêutico , Mitomicina , Mitomicinas/uso terapêutico
2.
Cancer Res ; 47(19): 5194-201, 1987 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-3621205

RESUMO

Establishment of cell lines in vitro from a human lung cancer xenograft in nude mice resulted in transformed mouse cell lines. The transformed mouse cell lines expressed both mouse-specific and human-specific histocompatibility antigens. Of 3 cell lines, 2 were tumorigenic in BALB/c nude mice but not in normal mice. Tumors formed by the transformed mouse cell lines were fibroblastoid and epithelioid by histology. In addition, tumors exhibited neuroepithelial differentiation by ultrastructural and immunohistochemical analysis. Phenotypically they were similar to the original patient and human xenograft tumor. These data suggest that previous reports of host cell transformation and induction of fibrosarcomas may not be true fibrosarcomas. Human DNA sequences were present in the tumorigenic cell lines, indicating that spontaneous transfection of human tumor DNA into host cells had occurred. The implication of these findings is that human genetic information has been transferred to primary mouse host fibroblasts, which resulted in a transformed as well as a differentiated phenotype.


Assuntos
Transformação Celular Neoplásica , Transplante de Neoplasias , Transfecção , Animais , Sequência de Bases , Linhagem Celular , DNA de Neoplasias/análise , Antígenos HLA/análise , Humanos , Cariotipagem , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Fenótipo , Transplante Heterólogo
3.
Cancer Res ; 42(7): 2899-2905, 1982 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-7083178

RESUMO

Recently, it has been shown that 1,2:5,6-dianhydrogalactitol (DAG) can cause reversible alterations in cell cycle kinetics. Following treatment of CHO cells in vitro and Ehrlich ascites tumor cells in vivo, significant increases in the fraction of cells in S phase were observed to occur, and this was followed by an increase in the fractions of cells in G2 and mitosis. Treatments with S or G2-M phase-specific drugs at the peak enrichment times after DAG was given resulted in greater cell kills than when given by any other schedule. We have extended these kinetics-directed drug schedule studies to human tumors in vivo. The first phase was to determine whether DAG could be used to perturb cell kinetics in vivo as effectively in patients as it was in vitro. In 14 of 17 tumors studied, increases in the S-phase fractions were observed (ranging from 30 to 240% increases). The hr at which the S-phase peaks were observed (post-DAG treatment) was variable among the patients and among the tumors studied. However, this points out the value of obtaining actual cell kinetics data from serially biopsied tumors growing on the body surface and illustrates the importance that these data may have in helping to select an optimal time at which to give an S phase-specific drug. If such tumor cell kinetics-directed scheduling is ultimately shown to be effective, it will represent a means of individualizing therapy for a large fraction of tumor patients whose tumors are growing on or near the surface of the body. The tumors utilized in these studies were squamous carcinomas of the head and neck, skin, anus, and cervix; adenocarcinomas of the breast and rectum; and malignant melanoma. The second phase of this study will be to determine the tumor responses in patients treated with such kinetics-directed schedules.


Assuntos
Ciclo Celular/efeitos dos fármacos , Dianidrogalactitol/uso terapêutico , Neoplasias/tratamento farmacológico , Álcoois Açúcares/uso terapêutico , Adenocarcinoma/tratamento farmacológico , Biópsia , Carcinoma de Células Escamosas/tratamento farmacológico , Dianidrogalactitol/administração & dosagem , Esquema de Medicação , Humanos , Cinética , Melanoma/tratamento farmacológico , Neoplasias/patologia
4.
J Clin Oncol ; 2(4): 316-9, 1984 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-6707719

RESUMO

A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. There was one complete remission (2.5%) of greater than 12 months duration; seven partial remissions (17.5%) of two, three, three, four, five, six and eight months duration; 11 with no change (27.5%) of one to 10 months duration; and 21 (52.5%) patients with increasing disease. Toxicity included neutropenia, neurotoxicity, phlebitis and cellulitis at the site of injection, alopecia, fever and chills, myalgias, and gastrointestinal toxicity. It was concluded that vindesine does have activity in some patients with metastatic malignant melanoma. Further studies in previously untreated patients are warranted.


Assuntos
Neoplasias Pulmonares/tratamento farmacológico , Melanoma/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Vimblastina/análogos & derivados , Adulto , Idoso , Avaliação de Medicamentos , Feminino , Gastroenteropatias/induzido quimicamente , Humanos , Leucopenia/induzido quimicamente , Neoplasias Pulmonares/secundário , Metástase Linfática , Masculino , Melanoma/secundário , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/induzido quimicamente , Neoplasias Cutâneas/secundário , Trombocitopenia/induzido quimicamente , Vimblastina/efeitos adversos , Vimblastina/uso terapêutico , Vindesina
5.
J Clin Oncol ; 2(6): 585-90, 1984 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-6327927

RESUMO

The Southwest Oncology Group entered 453 patients with extensive small cell carcinoma into a combined modality treatment program, involving a randomized comparison of three different chemotherapy regimens for remission induction, and of maintenance chemotherapy alone versus maintenance treatment with cycles of reinduction added at six and 12 months. In addition, there was systematic comparison of diagnosis by institutional pathologist versus review panel pathologist. No difference was observed among the three different induction arms with respect to the incidence of response to treatment (61%), complete response (16%), or survival duration (median, 31 weeks). Neither overall response rate nor survival are superior to previous results. However, patients who achieved a complete response demonstrated significant survival benefit if they were in the group who received reinduction chemotherapy, as opposed to maintenance alone. This observation may apply most importantly to patients with small cell lung cancer of limited extent, for whom complete response is achieved in a majority. Agreement of institutional and review panel pathologists on the diagnosis of small cell lung cancer was observed in 94% of reviewed cases. A final observation is that the omission of chest irradiation results in a dramatic increase in the incidence of initial relapse at the primary tumor site. This suggests that future studies will need to use better therapy for local control in responding patients.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Medula Óssea/efeitos dos fármacos , Neoplasias Encefálicas/secundário , Carcinoma de Células Pequenas/mortalidade , Carcinoma de Células Pequenas/radioterapia , Ensaios Clínicos como Assunto , Terapia Combinada , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Dactinomicina/administração & dosagem , Dactinomicina/efeitos adversos , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Humanos , Leucopenia/induzido quimicamente , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/radioterapia , Metotrexato/administração & dosagem , Metotrexato/efeitos adversos , Distribuição Aleatória , Estomatite/induzido quimicamente , Vincristina/administração & dosagem , Vincristina/efeitos adversos
6.
J Clin Oncol ; 2(5): 420-4, 1984 May.
Artigo em Inglês | MEDLINE | ID: mdl-6427416

RESUMO

The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma. This study was initiated to determine whether a kinetically designed sequential administration of these three drugs would be superior and whether the presence or absence of easily measurable tumor would imply differences in survival. To do so, the Southwest Oncology Group tested two schedules in a randomized study of 239 patients. Independent judgments of response were made by two authors with the same results. Equivalent response rates (23% of all eligible sequential and 30% simultaneous) and median survival durations (22 and 23 weeks, respectively) were seen. Patients with and without readily measurable tumors each lived a median of 22 weeks. Higher degrees of hematologic toxicity were associated with prolonged survival (median 27 weeks versus 20 weeks, p = 0.04). Patients treated by community oncologists were described as having higher response rates than those treated in major medical centers (64% versus 31%, p = 0.03). The meaning of this is questionable in that there were no statistical differences in survival or toxicity. Those with prior exposure to 5-fluorouracil had only a tendency, without statistical significance, for a slightly inferior response and survival.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Gástricas/tratamento farmacológico , Adenocarcinoma/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Doxorrubicina/administração & dosagem , Esquema de Medicação , Fluoruracila/administração & dosagem , Doenças Hematológicas/induzido quimicamente , Humanos , Mitomicina , Mitomicinas/administração & dosagem , Recidiva Local de Neoplasia , Distribuição Aleatória , Neoplasias Gástricas/patologia , Fatores de Tempo
7.
J Clin Oncol ; 3(5): 654-9, 1985 May.
Artigo em Inglês | MEDLINE | ID: mdl-3998782

RESUMO

A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapsed at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.


Assuntos
Interferon Tipo I/uso terapêutico , Mieloma Múltiplo/terapia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , DNA Recombinante , Esquema de Medicação , Avaliação de Medicamentos , Feminino , Doenças Hematológicas/etiologia , Humanos , Interferon Tipo I/efeitos adversos , Masculino , Pessoa de Meia-Idade , Recidiva
8.
J Clin Oncol ; 14(1): 46-51, 1996 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8558219

RESUMO

PURPOSE: To determine whether the addition of surgical ovariectomy to standard chemotherapy prolongs disease-free survival (DFS) and overall survival in premenopausal patients with estrogen receptor (ER)-positive operable breast cancer with positive axillary nodes. PATIENTS AND METHODS: Three hundred fourteen premenopausal patients with ER-positive, node-positive breast cancer were enrolled between July 1979 and July 1989. Patients were stratified according to number of involved nodes and type of primary surgery and randomized to receive either of the following: (1) cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously (i.v.) weekly for 1 year, fluorouracil (5-FU) 400 mg/m2 i.v. weekly for 1 year, vincristine .625 mg/m2 i.v. weekly for the first 10 weeks, and prednisone weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP); or (2) bilateral ovariectomy followed by CMFVP. RESULTS: The median follow-up time is 7.7 years and the maximum 13.2 years. Treatment arms are not significantly different with respect to either survival or DFS (one-sided log-rank, P = .55 and .70, respectively). The 7-year survival rate is 71% on the CMFVP arm and 73% on CMFVP plus ovariectomy. No significant differences were observed in node or receptor level subsets. CONCLUSION: We conclude that, in this study, the addition of ovariectomy did not improve results over chemotherapy alone in the treatment of premenopausal women with node-positive, ER-positive, operable breast cancer. Our sample size was too small to detect a small improvement. The death hazards ratio of CMFVP/CMFVP plus ovariectomy was 1.22 (95% confidence interval [CI], .79 to 1.89).


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/terapia , Ovariectomia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Distribuição de Qui-Quadrado , Terapia Combinada , Ciclofosfamida/administração & dosagem , Intervalo Livre de Doença , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Metástase Linfática , Metotrexato/administração & dosagem , Prednisona/administração & dosagem , Pré-Menopausa , Modelos de Riscos Proporcionais , Receptores de Estrogênio/análise , Taxa de Sobrevida , Vincristina/administração & dosagem
9.
J Clin Oncol ; 11(9): 1710-6, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8355037

RESUMO

PURPOSE: To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil [5-FU], vincristine, and prednisone [CMFVP]) in poor-prognosis breast cancer patients (estrogen receptor [ER]-negative, stage II to IIIA) would result in improved disease-free and overall survival rates. PATIENTS AND METHODS: Four hundred forty-five women with ER-negative node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) over a period of 5 years (1979 to 1984). Randomized assignments were made to either 1 or 2 years of adjuvant CMFVP. Doses were daily oral cyclophosphamide 60 mg/m2, intravenous (i.v.) weekly methotrexate 15 mg/m2, i.v. weekly 5-FU 400 mg/m2, i.v. weekly vincristine .625 mg/m2 for the first 10 weeks, and prednisone weeks 1 through 6 with doses decreasing from 30 mg/m2 to 10 mg/m2. RESULTS: The median follow-up duration is 8.6 years, with a maximum of 11.3 years. Treatment arms were not significantly different as regards either survival or disease-free survival rates (P = .33 and P = .24, respectively). The five-year survival rate is 57% on the 1-year arm and 62% on the 2-year arm. Patients with three or fewer nodes and premenopausal status were associated with improved survival. Compliance on the 2-year arm was poor, with only 37% completing the full 2 years of treatment. SWOG grade 3 to 4 toxicity was experienced by 47% of patients on the 1-year arm and by 52% on the 2-year arm. There were no treatment-related deaths. CONCLUSION: We conclude that 2-year adjuvant treatment with CMFVP is not an improvement over 1-year treatment. Moreover, 2 years of CMFVP is difficult to complete. However, the results are not definitely negative. A moderate improvement attributed to prolonged chemotherapy, especially among patients with four or more positive nodes, cannot be ruled out.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Receptores de Estrogênio/análise , Adulto , Idoso , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Ciclofosfamida/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Metástase Linfática , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Modelos de Riscos Proporcionais , Análise de Sobrevida , Fatores de Tempo , Vincristina/administração & dosagem
10.
J Clin Oncol ; 4(8): 1227-37, 1986 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-3525768

RESUMO

Four hundred forty previously untreated patients with active multiple myeloma were entered into a randomized trial (Southwest Oncology Group [SWOG] study 7927/28) comparing vincristine, melphalan, Cytoxan (Mead Johnson & Company, Evansville, Ind), and prednisone (VMCP) alternating with vincristine, BCNU, Adriamycin (Adria Laboratories, Columbus, Ohio) and prednisone (VBAP) with or without levamisole with vincristine, Cytoxan, and prednisone (VCP) with or without levamisole for induction therapy. The treatment groups were well balanced for all of the known major prognostic factors. Patients receiving VMCP-VBAP responded (greater than or equal to 75% regression) more frequently to induction therapy, both without (54%) and with (44%) levamisole v VCP without (28%) or with (28%) levamisole (P less than .001). In addition, patients receiving VMCP-VBAP (+/- levamisole) had a survival duration determined to be significantly increased by all forms of analysis: 48 and 33 months for VMCP-VBAP without and with levamisole v 29 and 26 months for VCP without and with levamisole (P = .011 overall). Levamisole did not improve response rates or survival duration (P greater than or equal to .1), nor did it prolong remission in the maintenance phase (P = .85). Analysis of SWOG study 7704/05 (updated April 1985) confirmed improved survival for combination therapy v MP, but no benefit for levamisole. The overall findings support the use of VMCP-VBAP as an excellent treatment option for remission induction in patients with active myeloma of all stages and prognostic categories.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Mieloma Múltiplo/tratamento farmacológico , Análise Atuarial , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carmustina/administração & dosagem , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Doenças Hematológicas/induzido quimicamente , Humanos , Levamisol/administração & dosagem , Melfalan/administração & dosagem , Mieloma Múltiplo/imunologia , Mieloma Múltiplo/mortalidade , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Prognóstico , Distribuição Aleatória , Vincristina/administração & dosagem
11.
J Clin Oncol ; 5(2): 286-91, 1987 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3543247

RESUMO

Ninety-seven patients with recurrent or metastatic renal cell carcinoma were randomized to receive recombinant interferon (IFN) alfa-2b (Intron A; Schering-Plough, Kenilworth, NJ) by either the subcutaneous (SC) or intravenous (IV) route. The SC dosage was 2 X 10(6) IU/m2 three times weekly, and the IV dose 30 X 10(6) IU/m2 for five consecutive days every 3 weeks. Dose escalation to a maximum of 10 X 10(6) IU/m2 SC and 50 X 10(6) IU/m2 IV was allowed for patients with minimal or absent toxicity. Five of 51 of the SC-treated patients (10%) and three of 46 of the IV-treated patients (7%) had a partial response (PR) or complete response (CR). Patients with prior nephrectomy, no prior treatment, and lack of bone metastases were most likely to respond, and a retrospective analysis of this subgroup revealed a 23% response rate. Achievement of response took from 3 weeks to 11 months, while response duration lasted from 3 to 31+ months. All responders had prior nephrectomy; six of eight had no prior chemotherapy or hormonal therapy; five had lung metastases, and none had bone metastases. Regardless of route, almost all patients developed a flu-like syndrome; however, grade 3 or greater toxicity was much more common for IV-treated patients. This trial demonstrates modest, but definite antitumor activity for recombinant interferon in advanced renal cell carcinoma. SC administration with lower dose and toxicity is as effective as treatment administered IV.


Assuntos
Carcinoma de Células Renais/terapia , Interferon Tipo I/uso terapêutico , Neoplasias Renais/terapia , Adulto , Idoso , Ensaios Clínicos como Assunto , Feminino , Humanos , Injeções Intravenosas , Injeções Subcutâneas , Interferon Tipo I/administração & dosagem , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Fatores de Tempo
12.
J Clin Oncol ; 3(10): 1318-24, 1985 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-3900301

RESUMO

Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML). Of 281 evaluable patients with favorable histologic types of ML, 171 (61%) achieved complete remission (CR) and there was no difference in CR rate, CR duration, or survival according to the type of initial treatment. Of 388 evaluable patients with unfavorable histologic types of ML, 194 (50%) achieved CR. Levamisole appeared to adversely affect CR rates in nodular mixed and nodular large-cell lymphoma and CR duration in patients with unfavorable histology ML. Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levamisole may have had an adverse impact on outcome in certain subtypes of ML.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Vacina BCG/administração & dosagem , Levamisol/administração & dosagem , Linfoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Vacina BCG/efeitos adversos , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Humanos , Levamisol/efeitos adversos , Linfoma/mortalidade , Linfoma/patologia , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Estudos Prospectivos , Distribuição Aleatória , Vincristina/administração & dosagem , Vincristina/efeitos adversos
13.
J Clin Oncol ; 12(10): 2078-85, 1994 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7931477

RESUMO

PURPOSE: To compare chemohormonal therapy, chemotherapy alone, and hormonal therapy alone in postmenopausal patients with estrogen receptor (ER)-positive operable breast cancer and positive axillary nodes with respect to survival and disease-free survival (DFS). PATIENTS AND METHODS: Eight hundred ninety-two postmenopausal women with ER-positive, node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) from July 1979 to March 1989 and 74 by the Eastern Cooperative Oncology Group (ECOG) between June 1987 and March 1989. Patients were stratified according to number of involved nodes and type of primary surgery and randomized to receive the following: (1) tamoxifen 10 mg twice daily by mouth for 1 year; (2) cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously (IV) weekly for 1 year, fluorouracil (5-FU) 400 mg/m2 IV weekly for 1 year, vincristine .625 mg/m2 IV weekly for the first 10 weeks, and prednisone during weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP); or (3) the combination of tamoxifen and CMFVP. RESULTS: The median follow-up duration is 6.5 years, with a maximum of 12.8 years. Treatment arms are not significantly different with respect to either survival or DFS (log-rank, 2 df, P = .82 and .23, respectively). The 5-year survival rate is 77% for the tamoxifen arm, 78% for CMFVP, and 75% for the combination. No significant differences were observed in node or receptor level subsets. Severe or worse toxicity was experienced by 56% of patients on CMFVP and 61% on CMFVP plus tamoxifen, compared with 5% on tamoxifen alone. CONCLUSION: CMFVP chemotherapy, either alone or in combination with tamoxifen, has not been shown to be superior to tamoxifen alone in the treatment of postmenopausal women with node-positive, ER-positive, operable breast cancer.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Linfonodos/patologia , Pós-Menopausa , Receptores de Estrogênio/metabolismo , Tamoxifeno/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/química , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Ciclofosfamida/administração & dosagem , Intervalo Livre de Doença , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Humanos , Metástase Linfática , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Modelos de Riscos Proporcionais , Estados Unidos , Vincristina/administração & dosagem
14.
J Clin Oncol ; 6(6): 947-54, 1988 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3286830

RESUMO

The Southwest Oncology Group (SWOG) colorectal adjuvant study 7510 went through two phases. From 1975 to 1977, 309 patients were randomized to chemotherapy alone or the same chemotherapy plus immunotherapy. From 1977 until 1980, 317 patients were randomized among the same two therapy programs and a control group. With a minimum follow-up in either phase of greater than 7 years, data are now mature. They show no difference in relapse-free survival (RFS) nor overall survival (OS) in either the two-way phase or in the three-way phase. There is no indication, except possibly in one very small subset, that the addition of immunotherapy to chemotherapy provides an improvement in OS or in RFS. Using data from patients accrued after randomization to the control group, we fail to find evidence that either chemotherapy alone or chemoimmunotherapy improves OS or RFS when contrasted to outcomes obtained by patients on the control arm. In fact, we have significant evidence, at the P = .016 level, that chemotherapy does not improve OS by at least 50%; we also have significant evidence, at the P = .011 level, that chemoimmunotherapy will not improve OS by at least 25%. No evidence of efficacy was demonstrated for either treatment regimen, even though enough therapy was given to result in significant toxicities. Acute toxicity was at least moderate, but not fatal, in 75% of patients. Recognizable delayed toxicity included rare cases of fatal renal failure and acute leukemia.


Assuntos
Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Colo/terapia , Neoplasias Retais/terapia , Adenocarcinoma/mortalidade , Adolescente , Adulto , Idoso , Vacina BCG/administração & dosagem , Ensaios Clínicos como Assunto , Neoplasias do Colo/mortalidade , Terapia Combinada , Feminino , Fluoruracila/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Retais/mortalidade , Semustina/administração & dosagem
15.
Leukemia ; 6(7): 708-14, 1992 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1625490

RESUMO

Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic intrathecal therapy in AML? (iii) Does late intensification affect treatment outcome? (iv) Does maintenance with levamisole affect disease-free survival or overall survival? Among 611 evaluable patients, 329 (54%) achieved complete remission. There was no difference in the remission rate between those patients receiving rubidazone (54%) and those receiving adriamycin (54%) as part of the induction regimen. Prophylactic intrathecal therapy with cytosine arabinoside had no effect on the incidence of central nervous system disease or survival. After nine months of complete remission, patients were randomized between late intensification with POMP (mercaptopurine + vincristine + methotrexate + prednisone) or continued maintenance with OAP (vincristine + cytosine arabinoside + prednisone). T patients randomized to late intensification had better survival and disease-free survival, compared to those randomized to receive no late intensification (p = 0.027 and 0.030, respectively). At twelve months of remission, surviving patients were randomized to receive levamisole or no further treatment. There was no evidence that levamisole affected survival or disease-free survival.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Daunorrubicina/análogos & derivados , Doxorrubicina/administração & dosagem , Leucemia Mieloide Aguda/terapia , Levamisol/administração & dosagem , Braquiterapia , Terapia Combinada , Daunorrubicina/administração & dosagem , Humanos , Imunoterapia , Mercaptopurina/uso terapêutico , Metotrexato/uso terapêutico , Neoplasias do Sistema Nervoso/prevenção & controle , Prednisona/uso terapêutico , Análise de Sobrevida , Vincristina/uso terapêutico
16.
Arch Intern Med ; 145(6): 1006-12, 1985 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3890786

RESUMO

In this Southwest Oncology Group (SWOG) study, 216 adults with acute leukemia were treated with ten-day chemotherapy consisting of vincristine sulfate (Oncovin), cytarabine (ara-C) (100 mg per square meter of body area per day by 24-hour infusion), and prednisone (ten-day OAP). The results were compared with those of a previous SWOG study in which cytarabine (200 mg per square meter of body area per day) was given for five days (five-day OAP). Patients entering complete remission (CR) were given three consolidation courses of five-day OAP and randomized to maintenance chemotherapy alone (32 patients) or combined with BCG vaccine (24 patients). For 160 previously untreated patients with acute myelogenous leukemia, there was no difference in remission rates (53% vs 43%) or median survival times (48 vs 47 weeks) between ten-day and five-day OAP. The difference in duration of CR (74 vs 54 weeks, respectively) between the two maintenance arms was not statistically significant. However, 14% of evaluable patients with acute myelogenous leukemia and 26% of those achieving CR were alive and in remission more than five years.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Vacina BCG/administração & dosagem , Leucemia/tratamento farmacológico , Doença Aguda , Adolescente , Adulto , Fatores Etários , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ensaios Clínicos como Assunto , Citarabina/administração & dosagem , Feminino , Humanos , Leucemia/patologia , Leucemia Linfoide/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Distribuição Aleatória , Fatores Sexuais , Fatores de Tempo , Vincristina/administração & dosagem
17.
Arch Intern Med ; 138(9): 1342-8, 1978 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-686922

RESUMO

Adults (274) with acute leukemia (AML) were randomly assigned to one of three treatment regimens: vincristine, prednisone, cytarabine--(1) 100 mg/sq m/day with cyclophosphamide (COAP); (2) 100 mg/sq m/day with daunorubicin (DOAP); and 200 mg/sq m/day (OAP). Cytarabine was infused continuously for five days. Patients entering complete remission randomly received maintenance treatment with COAP or OAP. For 197 previously untreated AML patients given COAP, DOAP, or OAP, remission rates were 37%, 35%, and 43%, respectively; median lengths, 40, 45, and 90 weeks; median survival, 7, 11, and 8 weeks. No statistically significant difference was found among treatments. Therefore, adding cyclophosphamide or daunorubicin, or using the COAP regimen with continuously infused cytarabine, produced no significant improvement over previously reported regimens. There was no significant difference in remission lengths in previously untreated AML patients maintained on OAP (median 81 weeks) or COAP (median 65 weeks).


Assuntos
Antineoplásicos/administração & dosagem , Leucemia/tratamento farmacológico , Doença Aguda , Adulto , Idoso , Ciclofosfamida/administração & dosagem , Citarabina/administração & dosagem , Daunorrubicina/administração & dosagem , Quimioterapia Combinada , Estudos de Avaliação como Assunto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Remissão Espontânea , Fatores de Tempo , Vincristina/administração & dosagem
18.
Exp Hematol ; 15(11): 1153-7, 1987 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-3678412

RESUMO

We have used collagenase to isolate cell populations from different compartments of mouse bone marrow. Cells were obtained from the shaft of the femur, the endosteum, and compact bone. We have studied the growth-enhancing effects of physiologically low oxygen levels on fibroblast colony-forming unit (CFU-F) growth in vitro. Low oxygen levels (0.1%-10% O2) increased CFU-F formation 1.8- to 2.8-fold. However, cells from the compact bone consistently grew with much higher efficiencies (12- to 31-fold) than did cells from femoral cavity and endosteal areas. These data indicate the usefulness of enzymatic methods of isolating cells from compartments of bone and the use of low oxygen atmosphere to enhance stromal cell growth in vitro.


Assuntos
Células da Medula Óssea , Células-Tronco Hematopoéticas/citologia , Oxigênio/toxicidade , Aerobiose , Animais , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Células Clonais , Masculino , Camundongos , Camundongos Endogâmicos ICR
19.
Semin Oncol ; 14(2 Suppl 2): 24-8, 1987 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3296211

RESUMO

Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years. Interferon (IFN) therapy has clearly influenced the levels of abnormal serum proteins in some patients. A multi-institutional phase II clinical trial used alfa-2b recombinant interferon (Intron A, Schering, Kenilworth, NJ) in 38 evaluable patients with relapsing and refractory multiple myeloma; two thirds of the patient population had received extensive prior treatment. Seven responded, of whom three continued to do so beyond 1 year--one with an ongoing complete remission. An additional 13 had at least a 25% decrease in abnormal paraproteins. Of nine patients who were initially refractory to chemotherapy, two responded to IFN. Of nine relapsing patients returned to chemotherapy following IFN therapy, six then responded. Thirty previously untreated patients with multiple myeloma were treated with IFN followed by melphalan and prednisone; of 24 evaluable patients, 18 responded with a median duration of 10+ months. Alfa-2b IFN apparently does not antagonize melphalan or prednisone, nor does it appear to worsen the response of the two drugs alone. Effectiveness of recombinant alfa-2b IFN in pretreated relapsing patients suggests additional trials are needed to study its effects in previously untreated patients. A significant number of patients who relapsed on their original chemotherapy and subsequent interferon will apparently respond to the reinstitution of chemotherapy.


Assuntos
Interferon Tipo I/uso terapêutico , Mieloma Múltiplo/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ensaios Clínicos como Assunto , Terapia Combinada , Humanos , Imunoterapia , Interferon Tipo I/efeitos adversos , Melfalan/administração & dosagem , Prednisona/administração & dosagem , Proteínas Recombinantes/uso terapêutico
20.
Am J Med ; 60(7): 1026-31, 1976 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-180801

RESUMO

The nephrotic syndrome complicating malignancy in the absence of renal vein thrombosis, amyloid or neoplastic infiltration of the kidney is an unusual occurrence. A case of diffuse, well differentiated, lymphocytic lymphoma and lipoid nephrosis documented by light microscopy, electron microscopy and immunofluorescent studies is reported. A review of the literature revealed 76 case reports in which the nephrotic syndrome was associated with neoplasia. The most frequently associated neoplasms are Hodgkin's disease, various carcinomas, nonHodgkin's lymphoma and leukemia in descending order. The most frequent renal lesion in patients with the nephrotic syndrome associated with various carcinomas is membranous glomerulonephritis (81 per cent) as opposed to patients with lymphomas or leukemias who have predominantly lipoid nephrosis (60 per cent). The evidence is reviewed suggesting that the lesions in membranous nephropathy are immunologically mediated by tumor or viral antigen-antibody complexes and in lipoid nephrosis perhaps by a defect in t-lymphocyte function.


Assuntos
Linfoma/complicações , Síndrome Nefrótica/complicações , Idoso , Animais , Anticorpos Antineoplásicos , Complexo Antígeno-Anticorpo , Antígenos de Neoplasias , Glomerulonefrite/complicações , Glomerulonefrite/etiologia , Doença de Hodgkin/complicações , Humanos , Rim/imunologia , Rim/patologia , Leucemia/complicações , Vírus da Leucemia Murina , Masculino , Camundongos , Nefrose/complicações , Síndrome Nefrótica/imunologia , Síndrome Nefrótica/patologia , Linfócitos T/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA